SpectraCell’s Lp-PLA2 test measures the amount of a specific enzyme in blood that occurs when there is an active atherosclerotic process that could lead to the rupture of plaque and cause a heart attack or stroke.
According to the company, the Lp-PLA2 test helps physicians to identify patients who would benefit from more aggressive therapy and is especially recommended for intermediate and high-risk patients.
Jan Troup, director of lipid science at SpectraCell, said: “What makes Lp-PLA2 so unique is that it is very specific to vascular inflammation, making it an excellent indicator of active atherosclerosis, which is otherwise difficult to detect through conventional methods.”